Abstracts Clinical Lymphoma, Myeloma & Leukemia September 2023 S438 three studies (79.3%) had a retrospective study design, including one that was both retrospective and prospective. Conclusions: Cancer-related cachexia and sarcopenia impact overall survival and progression-free survival. Underlying their pathophysiology is poorly understood. Biomarkers are being studied. Several cachexia prognostic scores are in development to improve prognostic ability. There is near non-existent representation of myeloid neoplasms. Both cachexia and sarcopenia impact quality of life. Ongoing prospective studies are needed to best support affected patients. Research supported by NIH-5K23NR018488-04. Keywords: ABCL, hematologic malignancies, cancer-related cachexia, cancerrelated sarcopenia, prognostic indicators ABCL-500 Longer Follow‑Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/ Refractory Large B‑Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL‑1 Trial Yasmin Karimi MD1, Herve Ghesquieres MD, Ph2, Wojciech Jurczak MD, PhD3, Chan Y. Cheah MBBS, FRACP, FRCPA, DMSc4, Michael Roost Clausen MD, PhD5, Pieternella Lugtenburg MD, PhD6, David Cunningham MD, FRCP, FMedSci7, Young Rok Do MD, PhD8, David John Lewis MD9, Robin Gasiorowski MBBS, FRACP, FRCPA, PhD10, Tae Min Kim MD, PhD11, Marjolein van der Poel MD, PhD12, Michelle Limei Poon MBBS, MRCP13, Tatyana Feldman MD14, Kim M. Linton MBChB, PhD15, Anna Sureda MD, PhD16, Martin Hutchings MD, PhD17, Mariana Cota Stirner MD, PhD18, Yan Liu PhD19, Nurgul Kilavuz PharmMS19, Mariana Sacchi MD19, Catherine Thieblemont MD, PhD20 1University of Michigan Comprehensive Cancer Center, Ann Arbor, USA. 2Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France. 3MSC National Research Institute of Oncology, Kraków, Poland. 4Sir Charles Gairdner Hospital, Nedlands, Australia. 5Vejle Hospital, Vejle, Denmark. 6On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands. 7The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. 8Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of. 9University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, United Kingdom. 10Concord Hospital, University of Sydney, Sydney, Australia. 11Seoul National University Hospital, Seoul, Korea, Republic of. 12On behalf of the Lunenburg Lymphoma Phase I/ II Consortium-HOVON/LLPC, Maastricht, Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands. 13National University Hospital, Singapore, Singapore. 14Hackensack Meridian Health Hackensack University Medical Center, Hackensack, USA. 15The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, United Kingdom. 16Institut Català d’Oncologia, Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain. 17Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 18AbbVie, North Chicago, USA. 19Genmab, Princeton, USA. 20Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France Context: Relapsed/refractory (R/R) large B-cell lymphoma (LBCL) is challenging to treat. Epcoritamab SC is a CD3xCD20 bispecific antibody approved by the FDA for the treatment of adults with R/R DLBCL, NOS, including DLBCL arising from indolent lymphoma, and HGBCL after ≥2 lines of systemic therapy. In the EPCORE™ NHL-1 trial, single-agent epcoritamab SC demonstrated deep, durable responses and a manageable safety profile in patients with R/R LBCL (Thieblemont et al, JCO 2023). Objective: We present updated results for single-agent epcoritamab in R/R LBCL, including DLBCL and HGBCL (EPCORE NHL-1, phase 1/2; NCT03625037). Patients: Patients with R/R CD20+ LBCL were included. As of November 18, 2022, 157 patients (148 DLBCL or HGBCL [efficacy population], 4 PMBCL, and 5 FL grade 3B) were treated. Interventions: Patients received epcoritamab SC (step-up doses 1 and 2 followed by 48-mg full doses) in 28-d cycles (Cs; QW, C1–3; Q2W, C4–9; Q4W, C≥10) until PD or unacceptable toxicity. Results: Median follow-up was 20 mo. Of 157 patients treated (median age, 64 y), 36 remain on treatment. Patients had a median of 3 prior treatment lines; 61% had primary refractory disease, and 39% had prior CAR T. The most common treatment-emergent adverse events of any grade (G) were CRS (51%), neutropenia (24%), pyrexia (24%), fatigue (23%), nausea (22%), and diarrhea (21%). Nine patients had G1–2 ICANS; 1 patient with multiple confounding factors had G5 ICANS, related to treatment. In addition, 1 fatal COVID-19 case was considered related to treatment. CRS was primarily low grade (48% G1–2, 3% G3) and occurred mostly following the first full dose (C1D15). Among patients with DLBCL or HGBCL (n=148; efficacy population), overall and complete response rates were 61% and 39%, respectively; notably, 39% had received prior CAR T. Median duration of response was 15.5 mo (95% CI, 9.7–20.8). Median overall survival was 18.5 mo and was not reached among complete responders. Conclusions: Longer follow-up reaffirms that single-agent epcoritamab SC induces durable complete remissions with favorable long-term outcomes and manageable safety in patients with R/R DLBCL or HGBCL. Keywords: bispecific, large B-cell lymphoma, hematologic malignancy, non-Hodgkin lymphoma ABCL-504 Population Health and Economic Benefits of Pola‑R‑CHP versus R‑CHOP in Patients With Previously Untreated Diffuse Large B‑Cell Lymphoma (DLBCL) in the United States Anthony Masaquel PhD, MPH1, Jia Li PhD1, Rodrigo Ho PharmB2, David Fox PharmD1, Katherine L. Rosettie
RkJQdWJsaXNoZXIy MTk3NTQxMg==